Ann: Imugene Presentation to JPMorgan Healthcare Conference, page-53

Hi TB, While I agree the information that was presented paints an amazing picture for the future of Imugene, the patients and ultimately the shareholders, I don't feel the presentation was at a very high level.
I am a staunch supporter of Leslie however she appeared to be nervous and definitely rushed through the presentation.
She didn't miss a beat and is clearly across her brief but the speed and tone of her presentation was little lacking.
We will see how those that attended viewed the presentation in the fullness of time, there certainly is a lot to take in for a 15 minute presentation, hopefully meetings behind the scenes provide opportunities for attendees to see a more relaxed Leslie who is able to expand on the information she presented.
The information itself paints a picture of a very strong biotechnology company, money in the bank, experienced & knowledgeable management, manufacturing capability, strong relationship with FDA and other regulatory authorities and of course amazing patent life.
All indicators, fundamental and Technical analysis point to a change in mood in the investment community for bio companies and barring events coming from left field on a macro level we should see some gains this year.
Above all else we should see medical advancement of the likes we have never seen, which hopefully will provide hope to those that are suffering from this insidious disease.
Thankyou for your views and knowledge you impart on this forum, it certainly helps to maintain confidence when things aren't looking so rosy.

DYOR opinion only